Artwork

Content provided by Bryn Mawr Communications (BMC) and Modern Optometry. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Bryn Mawr Communications (BMC) and Modern Optometry or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Treating OSD in 2024

25:13
 
Share
 

Manage episode 394373930 series 3274150
Content provided by Bryn Mawr Communications (BMC) and Modern Optometry. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Bryn Mawr Communications (BMC) and Modern Optometry or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Jackie Garlich, OD, FAAO, and Jessilin Quint, OD, MBA, MS, FAAO, kick off 2024 with a conversation about several new and anticipated products for treating ocular surface disease, including cyclosporine ophthalmic solution 0.1% (Vevye, Harrow), perfluorohexyloctane ophthalmic solution (Meibo, Bausch + Lomb), and lotilaner ophthalmic solution 0.25% (Xdemvy, Tarsus Pharmaceuticals). They also share some practice pearls and professional goals for the year ahead.

  continue reading

48 episodes

Artwork
iconShare
 
Manage episode 394373930 series 3274150
Content provided by Bryn Mawr Communications (BMC) and Modern Optometry. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Bryn Mawr Communications (BMC) and Modern Optometry or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Jackie Garlich, OD, FAAO, and Jessilin Quint, OD, MBA, MS, FAAO, kick off 2024 with a conversation about several new and anticipated products for treating ocular surface disease, including cyclosporine ophthalmic solution 0.1% (Vevye, Harrow), perfluorohexyloctane ophthalmic solution (Meibo, Bausch + Lomb), and lotilaner ophthalmic solution 0.25% (Xdemvy, Tarsus Pharmaceuticals). They also share some practice pearls and professional goals for the year ahead.

  continue reading

48 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide